A new University of Manchester study finds that analysing skin sebum via non-invasive swabs can identify Parkinson's biomarkers up to seven years before motor symptoms emerge, offering hope for earlier detection and intervention.
Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.
Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.
Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.
Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.
Dr Roderick Corriveau, PhD from the National Institute of Neurological Disorders & Stroke, part of the National Institutes of Health in the U.S., details the importance of understanding the many possible paths to dementia.
Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, provide an in-depth perspective on Huntington’s disease (HD) research.
Dr Timothy Kwok, Professor at The Chinese University of Hong Kong, shares the development of the Electronic Cognitive Screen (EC-Screen) for population screening of dementia in older people.
JPND, the largest global collaborative initiative for neurodegenerative disease research, creates a major impact on neurodegenerative research funding in Europe.
Prof Monica Di Luca, President, European Brain Council, sheds light on brain conditions, mental and neurological alike, starting with comment on the burdens presented.
Over 350 million people suffer from arthritis pain globally, which means significant levels of opiates are used to manage the condition - but what if there was a less addictive treatment?
Daniel Berman from Nesta Challenges and Colin Capper at the Alzheimer’s Society focus here on dementia tech, including comment on overcoming barriers to innovation post-pandemic.
Dementia UK’s Head of Research and Publications, Dr Karen Harrison Dening, discusses her thoughts on the diagnosis of dementia and the impact of COVID-19 on this.
